Skip to main content

COVID-19 Topic Center

Expert Insights

Commentary
In an effort to expand patients’ access to emergency refills of prescription medicines, the Ohio House of Representatives has just passed House Bill 37, increasing the number of times a year that a pharmacist can dispense a life-saving medication without a prescription. The Bill expands on House…
Commentary
By Douglas L. Jennings, PharmD, FACC, FAHA, FCCP, FHFSA, BCPS  Volume3, Issue 2 As the spring swings into full gear, vaccination totals are surging to new highs while COVID-19 case counts continue to drop across most of the nation. While these successes in preventing infections are incredibly…
Commentary
By Jill Paslier, PharmD, CSP, International Safe Medication Management Fellow at Institute for Safe Medication Practices (ISMP) When patients report community pharmacy mediation errors to ISMP, they are often more upset by the response, or lack of response from the pharmacy staff than with…
Commentary
By Soumya Vishwanath, PharmD, University of Massachusetts Medical School  The next wave of patient care is upon us: digital therapeutics (DTx)–evidence-based, clinically evaluated software products that treat, manage, and prevent diseases.1 The Food and Drug Administration (FDA) estimated that 325…
Commentary
By Douglas L. Jennings, PharmD, FACC, FAHA, FCCP, FHFSA, BCPS  Volume3, Issue 1 “Pour some sugar on me” SGLT2 inhibitors have morphed into somewhat of a pharmacologic panacea over the last half-decade. First, there was the serendipitous discovery of cardio-protective effects in patients with…
Commentary
Atrial fibrillation is a major health care disorder being the most common arrhythmia, is associated with low quality of life, increased risk of morbidity and mortality, and a very high cost burden.1 Advancing age and tobacco smoking, alcohol abuse, obesity, diabetes, myocardial infarction and heart…
Commentary
By Douglas L. Jennings, PharmD, FACC, FAHA, FCCP, FHFSA, BCPS  Volume 2, Issue 4 Recent data shows that despite all efforts from the heart failure community and in spite of contemporary guideline-directed medical therapy, deaths from heart failure (HF) continue to rise. The rates of death remain…
Commentary
By Douglas L. Jennings, PharmD, FACC, FAHA, FCCP, FHFSA, BCPS  Volume 2, Issue 3 Despite optimal medical therapy—which commonly consists of a cocktail of cardioprotective agents such as antiplatelet, statin, and antihypertensive medications—a significant number of patients with coronary artery…
Commentary
By Yvette C Terrie, BS Pharm, RPh, consultant pharmacist It’s over one year later and COVID-19 is still part of all of our lives. Great strides have been made in learning more about the transmission, prevention and treatment of COVID-19. Moreover, many individuals are trying their best to get back…
Video
Gregg Sylvester, MD, MPH, chief medical officer, and David Ross, vice president, commercial operations for North America, both at Seqirus, discuss the recent FDA approval for Flucelvax Quadrivalent, explain what the expanded indication means for care access, and how they foresee this new indication…
Back to Top